drugset / Trial / NCT01682187

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

NCT01682187

Phase 1 Completed 66 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study of oral LY2157299 as monotherapy and in combination with lomustine in participants with recurrent malignant glioma.

Timeline

Start
2005-12-15
Primary completion
2012-05-22
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule 40 mg Oral
Subject Galunisertib Small molecule 80 mg Oral
Subject Galunisertib Small molecule 150 mg Oral
Subject Galunisertib Small molecule 360 mg Oral
Subject Lomustine Small molecule Oral

Indications